|
HOME > STD News and Information > Hepatitis
InterMune Plummets After Halting Key Trial
InterMune (NasdaqGM:ITMN - News) shares tumbled on Mar. 6 after the Brisbane (Calif.)-based company halted late stage trials of a treatment for the lung condition idiopathic pulmonary fibrosis. Data from the Phase III clinical trial showed that the drug did not show a statistically significant improvement in mortality rates over a placebo for the disease. The stock dropped 21% to $22.15 in heavy ...
|
